SONOVEIN® High-Intensity Focused Ultrasound (HIFU) System

Indication
Lower extremity venous insufficiency and varicose veins; non-invasive treatment of saphenous vein reflux
Manufacturer
Theraclion (France)
Lecheng Status
First treatment in region completed (June 2026) at Boao Super Hospital
Available At
博鳌超级医院
Regulatory Status
FDA: Pivotal study completed; approval pending; EMA: Approved (CE marked; used in 30+ countries); NMPA: Not yet approved in mainland China

Common Questions

Who is eligible for this treatment?
Patients with confirmed indication and a treating physician referral. International patients need a medical visa (M visa).
How can I access this treatment in Lecheng?
Contact the hospital listed in the quick facts section. International patients can use medical agents or contact the hospital directly.
What is the cost of treatment?
Costs vary by treatment protocol and length of stay. Please contact the hospital for accurate pricing. International insurance may be accepted.

Indication: Lower extremity venous insufficiency and varicose veins; non-invasive treatment of saphenous vein reflux

Manufacturer: Theraclion (France)

World's first non-invasive HIFU treatment for varicose veins requiring no incisions, no punctures, and no general anesthesia. External ultrasound energy precisely targets the diseased vein under real-time imaging guidance. Over 4,000 treated limbs in the EU with 3+ years follow-up and no serious adverse events. FDA pivotal study showed 96.8% vein closure rate at 1 year. Developed by Theraclion (France). Offers a scar-free alternative to traditional vein stripping, laser, and radiofrequency ablation.

Sources & Citations

  1. hainanlecheng.com · accessed 2026-07-03